CN1842344A - 衍生自人血纤维蛋白原的Aα或Bβ链的肽用于治疗休克的用途 - Google Patents

衍生自人血纤维蛋白原的Aα或Bβ链的肽用于治疗休克的用途 Download PDF

Info

Publication number
CN1842344A
CN1842344A CNA2005800009931A CN200580000993A CN1842344A CN 1842344 A CN1842344 A CN 1842344A CN A2005800009931 A CNA2005800009931 A CN A2005800009931A CN 200580000993 A CN200580000993 A CN 200580000993A CN 1842344 A CN1842344 A CN 1842344A
Authority
CN
China
Prior art keywords
group
peptide
pro
arg
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800009931A
Other languages
English (en)
Chinese (zh)
Inventor
P·佩策尔鲍尔
K·查哈洛夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrex Medical Research and Development GmbH
Original Assignee
Fibrex Medical Research and Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Research and Development GmbH filed Critical Fibrex Medical Research and Development GmbH
Publication of CN1842344A publication Critical patent/CN1842344A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNA2005800009931A 2004-06-25 2005-06-24 衍生自人血纤维蛋白原的Aα或Bβ链的肽用于治疗休克的用途 Pending CN1842344A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA1087/2004 2004-06-25
AT0108704A AT414097B (de) 2004-06-25 2004-06-25 Pharmazeutische zubereitung zur behandlung von schock
ATA40/2005 2005-01-13

Publications (1)

Publication Number Publication Date
CN1842344A true CN1842344A (zh) 2006-10-04

Family

ID=35508712

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800009931A Pending CN1842344A (zh) 2004-06-25 2005-06-24 衍生自人血纤维蛋白原的Aα或Bβ链的肽用于治疗休克的用途

Country Status (4)

Country Link
CN (1) CN1842344A (de)
AT (1) AT414097B (de)
UA (1) UA91497C2 (de)
ZA (1) ZA200602053B (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101937002A (zh) * 2010-07-23 2011-01-05 合肥天一生物技术研究所 血红蛋白目测试剂
CN104519899A (zh) * 2012-03-15 2015-04-15 纽约州立大学研究基金会 包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法
CN116348128A (zh) * 2020-05-19 2023-06-27 F4医药有限责任公司 用于治疗病毒性内皮炎的Bβ15-42

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT502987A1 (de) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101937002A (zh) * 2010-07-23 2011-01-05 合肥天一生物技术研究所 血红蛋白目测试剂
CN104519899A (zh) * 2012-03-15 2015-04-15 纽约州立大学研究基金会 包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法
CN116348128A (zh) * 2020-05-19 2023-06-27 F4医药有限责任公司 用于治疗病毒性内皮炎的Bβ15-42

Also Published As

Publication number Publication date
ZA200602053B (en) 2007-06-27
AT414097B (de) 2006-09-15
UA91497C2 (ru) 2010-08-10
ATA10872004A (de) 2005-12-15

Similar Documents

Publication Publication Date Title
Mustafa et al. Cytokine storm in COVID‐19 patients, its impact on organs and potential treatment by QTY code‐designed detergent‐free chemokine receptors
TWI750189B (zh) 一種治療冠狀動脈粥樣硬化及其併發症的方法
JP5037331B2 (ja) 出血性障害の処置のための第ｉｘａ因子
BR122020017577B1 (pt) Método para purificar proteínas inibidoras inter-alfa
CN111565743A (zh) 用于治疗或预防冠状病毒感染的蛋白酶活性的肽
AU2005256121B2 (en) Use of peptides derived from the A alpha or B beta chain of human fibrinogen for the treatment of shock
CN108463236A (zh) 一种预防或治疗放射性和化学性损伤的方法
CN1842344A (zh) 衍生自人血纤维蛋白原的Aα或Bβ链的肽用于治疗休克的用途
JP2020526525A (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
US20230165943A1 (en) Tp508 acute therapy for patients with respiratory virus infection
WO2020232277A1 (en) Uses of a2 domain of von willebrand factor
JP2024539138A (ja) 多価効果を持つペプチド
JP2011506489A (ja) 止血をモジュレートする組成物およびその使用法
KR20060118486A (ko) 인자 ｘｉ의 치료적 사용
WO2021240371A1 (en) Methods and compositions for treatment of coronavirus infection and associated coagulopathy
AU2013375294B2 (en) Inhibition of tissue factor pathway inhibitor with factor Xa derivatives
RU2678332C1 (ru) Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
KR20070022636A (ko) 인간 섬유소원의 알파 또는 베타 체인으로부터 유래된펩티드의 쇼크 치료 용도
Jiang et al. The Effect of Heparin-Grafted Chitosan-Cellulose Composite Microspheres on the Removal of Endotoxins and Circulating Histones in a Septic Rabbit Model: An In Vivo Study
HK1093308B (en) Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock
WO2025221694A1 (en) Intravenous compositions of tissue kallikrein-1 and related methods
MXPA06002514A (en) Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock
Wernersson Mast Cell Proteases
BRPI0913949B1 (pt) Composição farmacêutica compreendendo proteínas inibidoras inter- alfa purificadas
MXPA06005477A (en) Therapeutic use of factor xi

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20061004